Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-driven decision study with adalimumab in early rheumatoid arthritis
ISRCTN61158084Phase 3Completed
- Sponsor
- Universitätsklinikum Regensburg
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of adalimumab in rheumatoid arthritis (RA), sponsored by Universitätsklinikum Regensburg. Primary endpoint: Disease Activity Score in 28 joints at 12 weeks. Started Jan 2009; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN61158084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61158084.